BioMarin Pharmaceutical Inc. (BMV:BMRN)
Mexico flag Mexico · Delayed Price · Currency is MXN
1,200.00
+100.00 (9.09%)
At close: Aug 5, 2025
9.09%
Market Cap213.61B
Revenue (ttm)57.77B
Net Income (ttm)12.39B
Shares Outn/a
EPS (ttm)64.10
PE Ratio17.23
Forward PE13.23
Dividendn/a
Ex-Dividend Daten/a
Volume35
Average Volume146
Open1,200.00
Previous Close1,100.00
Day's Range1,200.00 - 1,200.00
52-Week Range1,053.00 - 1,700.00
Betan/a
RSI39.95
Earnings DateAug 1, 2025

About Altair Engineering

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1996
Employees 3,040
Stock Exchange Mexican Stock Exchange
Ticker Symbol BMRN
Full Company Profile

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in GBP Financial Statements

News

There is no news available yet.